Skip to main content
Journal cover image

Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity.

Publication ,  Journal Article
Kharasch, ED; Hoffer, C; Bedynek, P
Published in: Clin Pharmacokinet
August 2024

BACKGROUND AND OBJECTIVES: Clearances and the area under the plasma concentration-time curve extrapolated to infinity (AUC0-∞) of intravenous (IV) and oral midazolam and alfentanil are probes for hepatic and first-pass cytochrome P450 3A (CYP3A) activity, drug interactions, and phenotyping. Single-time plasma concentrations are also used as a proxy for clearance and AUC0-∞. Pupil diameter change is a noninvasive surrogate for plasma alfentanil. An ideal probe should have minimal intrasubject (interday) variability. Despite their widespread use, the intrasubject variability of CYP3A probes is not well characterized. This investigation determined the intrasubject (interday) variability of midazolam and alfentanil metrics of hepatic and first-pass CYP3A. METHODS: Twelve volunteers were studied in a four-period protocol, with each period identical and separated by approximately 2 weeks. In each period, participants received 1 mg IV midazolam then 15 μg/kg IV alfentanil 1 h later. The next day, they received 3 mg oral midazolam then 60 μg/kg oral alfentanil. Plasma drug concentrations were determined by liquid chromatography-mass spectrometry (LCMS). Dark-adapted pupil diameters were measured coincident with blood sampling. Plasma concentrations and pupil effects (miosis) were analyzed using noncompartmental methods. The results were the coefficient of variation (%CV, mean ± SD) across four sessions in 12 participants. RESULTS: For IV midazolam: AUC0-∞, clearance, and 5 h concentration, the %CVs were 12 ± 3, 12 ± 3, and 18 ± 8. For IV alfentanil AUC0-∞, clearance, 2 h concentration, and area under the effect curve from time zero to infinity (AUEC0-∞), the %CVs were 16 ± 5, 15 ± 4, 22 ± 7, and 50 ± 28. For oral midazolam AUC0-∞, clearance, and 5 h concentration, %CVs were 19 ± 5, 18 ± 4, and 28 ± 11. For oral alfentanil: AUC0-∞, clearance, 4 h concentration, and AUEC0-∞, %CVs were 20 ± 4, 21 ± 4, 42 ± 26, and 37 ± 14. CONCLUSIONS: Midazolam and alfentanil had comparable intrasubject variabilities of clearance and AUC0-∞. Single-time point metrics had greater intrasubject variability than AUC0-∞ and clearance. Miosis was a surrogate for alfentanil concentrations and provided real-time results, but intrasubject variability was greater than that of clearances and AUC0-∞.

Duke Scholars

Published In

Clin Pharmacokinet

DOI

EISSN

1179-1926

Publication Date

August 2024

Volume

63

Issue

8

Start / End Page

1121 / 1135

Location

Switzerland

Related Subject Headings

  • Young Adult
  • Pupil
  • Pharmacology & Pharmacy
  • Midazolam
  • Male
  • Liver
  • Humans
  • Female
  • Cytochrome P-450 CYP3A
  • Area Under Curve
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kharasch, E. D., Hoffer, C., & Bedynek, P. (2024). Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity. Clin Pharmacokinet, 63(8), 1121–1135. https://doi.org/10.1007/s40262-024-01406-y
Kharasch, Evan D., Christine Hoffer, and Pamela Bedynek. “Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity.Clin Pharmacokinet 63, no. 8 (August 2024): 1121–35. https://doi.org/10.1007/s40262-024-01406-y.
Kharasch ED, Hoffer C, Bedynek P. Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity. Clin Pharmacokinet. 2024 Aug;63(8):1121–35.
Kharasch, Evan D., et al. “Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity.Clin Pharmacokinet, vol. 63, no. 8, Aug. 2024, pp. 1121–35. Pubmed, doi:10.1007/s40262-024-01406-y.
Kharasch ED, Hoffer C, Bedynek P. Intrasubject Variability in Intravenous and Oral Probes for Hepatic and First-Pass CYP3A Activity. Clin Pharmacokinet. 2024 Aug;63(8):1121–1135.
Journal cover image

Published In

Clin Pharmacokinet

DOI

EISSN

1179-1926

Publication Date

August 2024

Volume

63

Issue

8

Start / End Page

1121 / 1135

Location

Switzerland

Related Subject Headings

  • Young Adult
  • Pupil
  • Pharmacology & Pharmacy
  • Midazolam
  • Male
  • Liver
  • Humans
  • Female
  • Cytochrome P-450 CYP3A
  • Area Under Curve